About Oxytocin receptor
Oxytocin receptor (OXTR) is a protein
from Homo sapiens identified by UniProt accession
P30559, 389 residues long.
MolForge cross-references it against 0 known binders and
345 disease associations.
Target properties
| Protein name | Oxytocin receptor |
|---|
| UniProt accession | P30559 |
|---|
| Gene | OXTR |
|---|
| Organism | Homo sapiens |
|---|
| Length | 389 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Approved drugs hitting this target (6)
DrugCentral-linked approved drugs that act on this protein.
Disease associations (345)
Diseases linked to this target (Open Targets).
- postpartum hemorrhage · score 0.60
- hemorrhage · score 0.57
- premature birth · score 0.56
- pregnancy · score 0.56
- schizophrenia · score 0.53
- obesity · score 0.51
- autism spectrum disorder · score 0.49
- alcohol dependence · score 0.49
- Chronic pain · score 0.48
- adverse effect · score 0.46
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P30559-F1 | alphafold | PREDICTED | 78.62 | — |
Amino-acid sequence (389 residues)
MEGALAANWS AEAANASAAP PGAEGNRTAG PPRRNEALAR VEVAVLCLIL LLALSGNACV LLALRTTRQK HSRLFFFMKH LSIADLVVAV FQVLPQLLWD ITFRFYGPDL LCRLVKYLQV VGMFASTYLL LLMSLDRCLA ICQPLRSLRR RTDRLAVLAT WLGCLVASAP QVHIFSLREV ADGVFDCWAV FIQPWGPKAY ITWITLAVYI VPVIVLAACY GLISFKIWQN LRLKTAAAAA AEAPEGAAAG DGGRVALARV SSVKLISKAK IRTVKMTFII VLAFIVCWTP FFFVQMWSVW DANAPKEASA FIIVMLLASL NSCCNPWIYM LFTGHLFHEL VQRFLCCSAS YLKGRRLGET SASKKSNSSS FVLSHRSSSQ RSCSQPSTA
Explore Oxytocin receptor with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets